1. Home
  2. LYEL vs CHEC Comparison

LYEL vs CHEC Comparison

Compare LYEL & CHEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

SELL

Current Price

$13.64

Market Cap

195.8M

Sector

Health Care

ML Signal

SELL

CHEC

Chenghe Acquisition III Co. Class A Ordinary Share

SELL

Current Price

$10.33

Market Cap

175.5M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
LYEL
CHEC
Founded
2018
2024
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
195.8M
175.5M
IPO Year
2021
2025

Fundamental Metrics

Financial Performance
Metric
LYEL
CHEC
Price
$13.64
$10.33
Analyst Decision
Buy
Analyst Count
8
0
Target Price
★ $37.63
N/A
AVG Volume (30 Days)
★ 212.6K
21.8K
Earning Date
11-04-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $36,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$7.20
$9.91
52 Week High
$45.00
$10.56

Technical Indicators

Market Signals
Indicator
LYEL
CHEC
Relative Strength Index (RSI) 54.63 72.60
Support Level $12.25 $10.22
Resistance Level $14.97 $10.47
Average True Range (ATR) 1.67 0.02
MACD -0.18 0.00
Stochastic Oscillator 43.74 100.00

Price Performance

Historical Comparison
LYEL
CHEC

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

About CHEC Chenghe Acquisition III Co. Class A Ordinary Share

Chenghe Acquisition III Co is blank check company.

Share on Social Networks: